--- title: 'Funding Daily Summary: What Happened on November 5, 2026' headline: Alethio raises $90 million to take blood-cancer antibody toward trials description: T-Therapeutics raised $133 million for two T-cell engager programs targeting cancer and autoimmune diseases. url: https://thebench.bio/news/funding/2026-11-05 topic: funding date: '2026-11-05' covers: - '2026-11-05' date_published: '2026-11-05T12:09:31Z' date_modified: '2026-11-05T12:09:31Z' tags: - Funding sources: 3 publisher: TheBench.Bio --- # Funding Daily Summary: What Happened on November 5, 2026 **Alethio raises $90 million to take blood-cancer antibody toward trials** T-Therapeutics raised $133 million for two T-cell engager programs targeting cancer and autoimmune diseases. ## Today in brief Alethio secured $90 million for ATX-011, an antibody targeting G6B, and other drug candidates. [1] [2] T-Therapeutics brought in $133 million to advance two experimental T-cell engager programs toward clinical testing. [3] ## Alethio raises $90 million for blood-cancer programs Alethio Therapeutics raised $90 million in a Series A co-led by Sofinnova Partners and RA Capital. [1] Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford also participated. [1] Alethio plans to take its G6B-targeting antibody ATX-011 through Phase 1/2a studies, aiming to prepare it for Phase 3. [1] Alethio CEO Rohit Batta expects enrollment to start during the first six months of 2028, pending regulatory processes. [1] The company plans to test ATX-011 first in essential thrombocythemia, a blood cancer in the myeloproliferative neoplasms group. [1] Research using samples from more than 100 people with these disorders found G6B on abnormal stem cells, but not healthy blood stem cells. [1] Experiments reported at the 2026 American Society of Hematology annual meeting found that ATX-011 did not activate human platelets or disrupt megakaryocyte maturation in a cell model. [1] In two nonhuman primates, platelet counts fell 80% after 96 hours, then recovered as the antibody cleared. [1] Modeling suggests dosing every three to four weeks might maintain normal platelet counts in patients, a possibility that still requires clinical testing. [1] ## T-Therapeutics raises $133 million for two engager programs T-Therapeutics raised $133 million in an oversubscribed Series B to advance two experimental T-cell engager programs for cancer and autoimmune diseases. [3] Advent Life Sciences and British Business Bank jointly led the round. Johnson & Johnson Innovation, Samsara BioCapital, M-Ventures and Eli Lilly joined as new investors. [3] The company aims to take both lead programs to clinical proof of concept. [3] Its platform uses engineered mice to find human T-cell receptors, then incorporates them into bispecific molecules that bind a disease-associated target and CD3 on T cells. [3] Chief executive Dominic Schmidt said the approach could make targets inside cells accessible to the drugs and potentially improve safety. [3] T-Therapeutics appointed Kirsty Crame as chief development officer. [3] ## The day in numbers - **$90 million**: Alethio Therapeutics' Series A to advance ATX-011 and other drug candidates. [1] [2] - **$133 million**: T-Therapeutics' Series B for two experimental T-cell engager programs. [3] - **First half of 2028**: Alethio's expected start for ATX-011 enrollment, subject to regulatory processes. [1] ## Sources 1. [Oxford spinout Alethio raises $90M Series A for chronic blood cancer trials](), European Biotechnology, 2026-11-05 2. [Alethio raises $90M to target rare blood cancers](), BioPharma Dive, 2026-11-05 3. [T-Therapeutics raises $133M to bring TCR bispecifics into clinic](), European Biotechnology, 2026-11-05 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: